Bg pattern

RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS)

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS)

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Relvar Ellipta 92 micrograms/22 micrograms inhalation powder (single dose)

Relvar Ellipta 184 micrograms/22 micrograms inhalation powder (single dose)

fluticasone furoate/vilanterol

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What Relvar Ellipta is and what it is used for
  2. What you need to know before you use Relvar Ellipta
  3. How to use Relvar Ellipta
  4. Possible side effects
  5. Storing Relvar Ellipta
  6. Contents of the pack and other information

Step-by-step instructions for use

1. What Relvar Ellipta is and what it is used for

Relvar Ellipta contains two active substances: fluticasone furoate and vilanterol. There are two different strengths of Relvar Ellipta: fluticasone furoate 92 micrograms/vilanterol 22 micrograms and fluticasone furoate 184 micrograms/vilanterol 22 micrograms.

The 92/22 micrograms strength is used for the regular treatment of chronic obstructive pulmonary disease (COPD) in adults, as well as for the treatment of asthma in adults and adolescents aged 12 years and older.

The 184/22 micrograms strength is used for the treatment of asthma in adults and adolescents aged 12 years and older. The 184/22 micrograms strength is not approved for the treatment of COPD.

Relvar Ellipta should be used every day and not just when you have difficulty breathing or other symptoms of asthma and COPD. It should not be used to relieve a sudden attack of shortness of breath or wheezing. If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol). Contact your doctor if you do not have a fast-acting inhaler.

Fluticasone furoate belongs to a group of medicines called corticosteroids, often simply called steroids. Corticosteroids reduce inflammation. They also reduce swelling (inflammation) and irritation of the small airways in the lungs and gradually relieve breathing problems. Corticosteroids also help prevent asthma attacks and worsening of COPD.

Vilanterol belongs to a group of medicines called long-acting bronchodilators. It works by relaxing the muscles of the small airways in the lungs. This helps to open up the airways and makes it easier for air to get in and out of the lungs. When used regularly, it helps to keep the small airways in the lungs open.

Using these two active substances together every day will help control your breathing problems better than using either medicine on its own.

Asthmais a serious, chronic lung disease in which the muscles around the smaller airways tighten (bronchoconstriction) and become swollen and irritated (inflammation). Symptoms come and go and include difficulty breathing, wheezing, chest tightness, and coughing. Relvar Ellipta has been shown to reduce asthma attacks and symptoms.

Chronic Obstructive Pulmonary Disease (COPD)is a serious, chronic lung disease in which the airways become inflamed and thickened. Symptoms include difficulty breathing, coughing, chest discomfort, and coughing up mucus. Relvar Ellipta has been shown to reduce flare-ups of symptoms in COPD.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Relvar Ellipta

Do not use Relvar Ellipta

  • if you are allergicto fluticasone furoate, vilanterol, or any of the other ingredients of this medicine (listed in section 6)
  • do not use Relvar Elliptauntil you have talked to your doctor.

Warnings and precautions

Talk to your doctor before you start using Relvar Ellipta:

  • if you have liver problems, as you may be more likely to get side effects. If you have moderate or severe liver problems, your doctor will limit your dose to the lowest strength of Relvar Ellipta (92/22 micrograms once daily)
  • if you have heart problemsor high blood pressure
  • if you have pulmonary tuberculosis (TB)or any other long-standing or untreated infection
  • if you have ever been told you have diabetesor high blood sugar levels
  • if you have thyroid problems
  • if you have low potassium levels in your blood
  • if you have blurred vision or other vision problems.

Talk to your doctorbefore using this medicine if you think any of the above applies to you.

While you are using Relvar Ellipta

Sudden breathing problems

If you get chest tightness, coughing, wheezing, or difficulty breathing immediately after using your Relvar Ellipta inhaler:

stop using this medicineandget medical help immediately, as you may have a serious condition called paradoxical bronchospasm.

  • Talk to your doctor if you get blurred vision or other vision problems.
  • Talk to your doctor if you get an increased thirst, passing more urine than usual, or unexplained tiredness (signs of high blood sugar levels).

Lung infection

If you are using this medicine for COPD, you may be more likely to get a lung infection called pneumonia. See section 4 for information on symptoms to look out for while you are using this medicine. Talk to your doctor as soon as possible if you get any of these symptoms.

Children and adolescents

Do not give this medicine to children under 12 years of age for the treatment of asthma, or to children and adolescents of any age for the treatment of COPD.

Other medicines and Relvar Ellipta

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Talk to your doctor or pharmacist if you are not sure what your medicine contains.

Some medicines may affect how Relvar Ellipta works, or make it more likely that you will get side effects. These include:

  • medicines called beta-blockers, such as metoprolol, used to treat high blood pressureor heart disease
  • ketoconazole, used to treat fungal infections
  • ritonavir or cobicistat, used to treat HIV
  • long-acting beta2-adrenergic agonists, such as salmeterol.

Talk to your doctor or pharmacistif you are taking any of these medicines.

Some medicines may increase the effects of Relvar Ellipta, so your doctor may want to monitor you closely if you are taking these medicines.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine. If you are pregnant, do not use this medicine unless your doctor tells you to.

It is not known if this medicine passes into breast milk. Talk to your doctorbefore using Relvar Ellipta if you are breast-feeding. If you are breast-feeding, do not use this medicine unless your doctor tells you to.

Driving and using machines

It is unlikely that this medicine will affect your ability to drive or use machines.

Relvar Ellipta contains lactose

If your doctor has told you that you have an intolerance to some sugars, talk to your doctor before using this medicine.

3. How to use Relvar Ellipta

Always use this medicine exactly as your doctor has told you.If you are not sure, talk to your doctor or pharmacist.

Asthma

The recommended dosefor the treatment of asthma is one inhalation (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) once daily, at the same time each day.

If you have severe asthma, your doctor may decide that you should use one inhalation of the higher strength inhaler (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol). This dose should also be used once daily, at the same time each day.

COPD

The recommended dosefor the treatment of COPD is one inhalation (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) once daily, at the same time each day.

The higher strength of Relvar Ellipta (184 micrograms of fluticasone furoate and 22 micrograms of vilanterol) is not suitable for the treatment of COPD.

Relvar Ellipta is for inhalation only.

Use Relvar Ellipta at the same time each day, as it is effective for 24 hours

It is very important that you use this medicine every day, as prescribed by your doctor. This will help you to not have symptoms during the day or night.

Relvar Ellipta should not be used to relieve a sudden attack of shortness of breath or wheezing. If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol).

If you feel like you are getting short of breath or wheezing more often than usual, or if you are using your fast-acting "rescue" inhaler more often than usual, talk to your doctor.

How to use Relvar Ellipta

For full instructions on how to use Relvar Ellipta, see the "Step-by-step instructions for use" at the end of this leaflet.

Relvar Ellipta is for inhalation only. You do not need to prepare Relvar Ellipta in any special way, even the first time you use it.

If your symptoms do not improve

If your symptoms (shortness of breath, wheezing, coughing) do not improve or get worse, or if you are using your fast-acting "rescue" inhaler more often than usual: talk to your doctor as soon as possible.

If you use more Relvar Ellipta than you should

If you accidentally inhale more Relvar Ellipta than your doctor has prescribed, talk to your doctor or pharmacist. If possible, show them the inhaler, packaging, or this leaflet. You may notice that your heart beats faster than usual, feel shaky, or get a headache.

If you have used more medicine than you should for a long time, it is especially important that you talk to your doctor or pharmacist.This is because higher doses of Relvar Ellipta may reduce the amount of steroid hormones produced by your body.

If you forget to use Relvar Ellipta

Do not take a double dose to make up for a forgotten dose.Take your next dose at the usual time.

If you get wheezing or shortness of breath, or develop any other symptoms of an asthma attack, use your fast-acting "rescue" inhaler(such as salbutamol), and talk to your doctor.

Do not stop using Relvar Ellipta without talking to your doctor

Use this medicine for as long as your doctor tells you to. It will only work if you use it every day. Do not stop using it unless your doctor tells you to, even if you feel better.

If you have any questions about using Relvar Ellipta, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

Allergic reactions are rare (may affect up to 1 in 1,000 people)

If you get any of the following symptoms after using Relvar Ellipta, stop using this medicine and talk to your doctor immediately:

  • skin rash (hives) or redness
  • swelling, sometimes of the face or mouth (angioedema)
  • increased wheezing, coughing, or difficulty breathing
  • a sudden feeling of weakness or dizziness (which may cause collapse or loss of consciousness).

Sudden breathing problems

Sudden breathing problems after using Relvar Ellipta are rare.

If your breathing or wheezing gets worse immediately after using this medicine, stop using itand get medical help immediately.

Pneumonia (lung infection)in patients with COPD (common side effect, may affect up to 1 in 10 people).

If you get any of the following symptoms while using Relvar Ellipta, talk to your doctor. They could be symptoms of a lung infection:

  • fever or chills
  • increased production of mucus, change in the color of the mucus
  • increased coughing or difficulty breathing.

Other side effects:

Very common side effects

May affect more than 1 in 10people:

  • headache
  • common cold.

Common side effects

May affect up to 1 in 10people:

  • thrush (candidiasis), a fungal infection in the mouth or throat. Rinsing your mouth with water immediately after using Relvar Ellipta may help prevent this side effect
  • bronchitis (inflammation of the airways)
  • infection of the sinuses or throat
  • flu
  • pain or irritation in the back of the mouth and throat
  • sinusitis (inflammation of the sinuses)
  • itching, runny nose, or stuffy nose
  • coughing
  • changes in your voice
  • weakening of the bones, which may cause fractures
  • stomach pain
  • back pain
  • fever
  • joint pain
  • muscle spasms.

Uncommon side effects

May affect up to 1 in 100people:

  • irregular heartbeat
  • blurred vision
  • high blood sugar levels (hyperglycemia).

Rare side effects

May affect up to 1 in 1,000people:

  • fast heartbeat (tachycardia)
  • awareness of your heartbeat (palpitations)
  • shakiness
  • anxiety.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Relvar Ellipta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton, tray, and inhaler after EXP. The expiry date is the last day of the month stated.

Keep the inhaler in the sealed tray to protect it from moisture and only remove it immediately before first use. Once the tray is opened, the inhaler can be used for 6 weeks. Write the date that you open the tray on the inhaler label and the date that you should throw the inhaler away. The date should be written as soon as the inhaler is removed from the tray.

Do not store above 25°C.

If you store it in the refrigerator, let the inhaler come to room temperature for at least one hourbefore you use it.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Container Contents and Additional Information

Composition of Relvar Ellipta

  • The active ingredients are fluticasone furoate and vilanterol.
  • For the 92/22 microgram dose: each inhalation provides a delivered dose (dose that comes out of the mouthpiece) of 92 micrograms of fluticasone furoate and 22 micrograms of vilanterol (as trifenatate).
  • For the 184/22 microgram dose: each inhalation provides a delivered dose (dose that comes out of the mouthpiece) of 184 micrograms of fluticasone furoate and 22 micrograms of vilanterol (as trifenatate).
  • The other ingredients are lactose monohydrate (see section 2 “Relvar Ellipta contains lactose”) and magnesium stearate.

Appearance of the Product and Container Contents

Relvar Ellipta is a powder for inhalation (single-dose).

The Ellipta inhaler is a light grey inhaler with a yellow mouthpiece cover and a dose counter. It is packaged in a foil laminate tray with a foil lid. The tray contains a desiccant sachet to reduce moisture in the container. Once the tray lid is opened, discard the desiccant sachet, do not ingest or inhale it. The inhaler does not need to be stored in the foil laminate tray once it has been opened.

Relvar Ellipta is available in inhalers containing 14 or 30 doses (for 14 or 30 days of treatment) and in clinical packs of 90 doses (3 inhalers of 30 doses, for 90 days of treatment). Not all pack sizes may be marketed.

Marketing Authorisation Holder:

GlaxoSmithKline Trading Services Limited

12 Riverwalk

Citywest Business Campus

Dublin 24

Ireland

D24 YK11

Manufacturer:

Glaxo Wellcome Production

Zone Industrielle No.2

23 Rue Lavoisier

27000 Evreux

France

You can request more information about this medicinal product from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Tél/Tel: + 32 (0) 10 85 52 00

Lietuva

UAB “BERLIN-CHEMIE MENARINI BALTIC”

Tel: +370 52 691 947

[email protected]

Text in Bulgarian language with contact information of a pharmaceutical company and their email address

Luxembourg/Luxemburg

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Belgique/Belgien

Tél/Tel: + 32 (0) 10 85 52 00

Ceská republika

GlaxoSmithKline s.r.o.

Tel: + 420 222 001 111

[email protected]

Magyarország

Berlin-Chemie/A. Menarini Kft.

Tel.: +36 23501301

[email protected]

Danmark

GlaxoSmithKline Pharma A/S

Tlf.: + 45 36 35 91 00

[email protected]

Malta

GlaxoSmithKline Trading Services Limited

Tel: +356 80065004

Deutschland

BERLIN-CHEMIE AG

Tel: +49 (0) 30 67070

Nederland

GlaxoSmithKline BV

Tel: + 31 (0) 33 2081100

Eesti

OÜ Berlin-Chemie Menarini Eesti

Tel: +372 667 5001

[email protected]

Norge

GlaxoSmithKline AS

Tlf: + 47 22 70 20 00

Ελλáδα

Menarini Hellas A.E.

Τηλ: +30 210 83161 11-13

Österreich

GlaxoSmithKline Pharma GmbH

Tel: + 43 (0)1 97075 0

[email protected]

España

GlaxoSmithKline, S.A.

Tel: + 34 900 202 700

[email protected]

Polska

GSK Services Sp. z o.o.

Tel.: + 48 (0)22 576 9000

France

Laboratoire GlaxoSmithKline

Tél.: + 33 (0)1 39 17 84 44

[email protected]

Hrvatska

Berlin-Chemie Menarini Hrvatska d.o.o.

Tel: +385 1 4821 361

[email protected]

Portugal

GlaxoSmithKline – Produtos Farmacêuticos, Lda. Tel: + 351 21 412 95 00

[email protected]

România

GlaxoSmithKline Trading Services Limited

Tel: +40 800672524

Ireland

GlaxoSmithKline Trading Services Limited

Tel: + 353 (0)1 4955000

Slovenija

Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o.

Tel: +386 (0)1 300 2160

[email protected]

Ísland

Vistor hf.

Sími: + 354 535 7000

Slovenská republika

Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o.

Tel: +421 2 544 30 730

[email protected]

Italia

GlaxoSmithKline S.p.A.

Tel: + 39 (0)45 7741111

Suomi/Finland

GlaxoSmithKline Oy

Puh/Tel: + 358 (0)10 30 30 30

Κúπρος

GlaxoSmithKline Trading Services Limited

Τηλ: +357 80070017

Sverige

GlaxoSmithKline AB

Tel: + 46 (0)8 638 93 00

[email protected]

Latvija

SIA Berlin-Chemie/Menarini Baltic

Tel: +371 67103210

[email protected]

Date of Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency web site: http://www.ema.europa.eu.

Step-by-Step Instructions for Use

What is the Ellipta Inhaler?

The first time you use Relvar Ellipta, you do not need to check that it is working correctly, it comes ready to use. Just follow these step-by-step instructions.

Open box with inhaler, tray, leaflet, desiccant, and tray lid shown individually with descriptive labels

The inhaler is packaged in a tray. Do not open the tray until you are ready to start using your new medicine. When you are ready to use your inhaler, remove the lid to open the tray. The tray contains a desiccantsachet, to reduce moisture. Discard the desiccant sachet, do not open, ingest, or inhale it.

Hand disposing of empty blister pack in trash can with arrow indicating direction and separate desiccant

When you take the inhaler out of the tray, it will be in the "closed" position. Do not open the inhaleruntil you are readyto inhale a dose of medicine.When the tray is opened, you should write the "Discard by" date on the space provided on the inhaler label. The "Discard by" date is 6 weeks from the date of opening the tray. After this date, the inhaler should not be used.The tray can be discarded after first opening.

If stored in the refrigerator, allow the inhaler to come to room temperature for at least 1 hour before use.

The step-by-step instructions for the 30-dose Ellipta inhaler (30 days of treatment) also apply to the 14-dose Ellipta inhaler (14 days of treatment).

  1. Read the following instructions before using the inhaler

If you open and close the cover without inhaling the medicine, you will lose a dose.

The lost dose will be retained safely inside the inhaler, but it will not be available for inhalation.

It is not possible to accidentally take an extra dose or a double dose with one inhalation.

Dose counter of inhaler showing number 30 with arrows indicating cover and decreasing dose when used

  1. Prepare a dose

Before opening the cover, wait until you are ready to inhale a dose. Do not shake the inhaler.

  • Slide the cover down until you hear a "click".

Device with mouthpiece and ventilation slots, arrow indicating rotation with “click” sound and number 29 on base

The medicine is now ready to be inhaled.

As confirmation, the dose counter decreases by 1unit.

  • If the dose counter does not decrease when you hear the "click", the inhaler will not release the medicine.Take it to your pharmacist and ask for help.
  1. Inhale the medicine
  • Hold the inhaler away from your mouth, breathe out as much as is comfortable. Do notbreathe out into the inhaler.
  • Place the mouthpiece between your lips, and close your lips firmly around the mouthpiece.Do notblock the ventilation slots with your fingers.

Mouth with inhaler, lips adjusted to contoured mouthpiece, hand holding device, and text indicating not to block slot

  • Take a long, steady, deep breath in. Hold your breath for as long as is comfortable (at least 3-4 seconds).
  • Remove the inhaler from your mouth.
  • Breathe out slowly and gently.

You may not be able to taste or feel the medicine, even when you use the inhaler correctly.

If you want to clean the mouthpiece, use a dry tissue beforeclosing the cover.

  1. Close the inhaler and rinse your mouth
  • Slide the cover back up as far as it will go to cover the mouthpiece.

Auto-injector device with partially retracted protective cover showing activation button numbered 29

  • Rinse your mouth with water, after using the inhaler, do not swallow.

This will make it less likely that you will experience side effects such as mouth or throat ulcers.

Online doctors for RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS)

Discuss questions about RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS), including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS)?
RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS) requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS)?
The active ingredient in RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS) is vilanterol and fluticasone furoate. This information helps identify medicines with the same composition but different brand names.
How much does RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS) cost in pharmacies?
The average pharmacy price for RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS) is around 44.8 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS)?
RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS) is manufactured by Glaxosmithkline (Ireland) Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS) online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS) is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to RELVAR ELLIPTA 92 mcg/22 mcg INHALATION POWDER (UNIDODIS)?
Other medicines with the same active substance (vilanterol and fluticasone furoate) include RELVAR ELLIPTA 184 mcg/22 mcg INHALATION POWDER (UNIDODIS), REVINTY ELLIPTA 184 micrograms/22 micrograms inhalation powder (single dose), REVINTY ELLIPTA 92 micrograms/22 micrograms inhalation powder (single dose). These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media